Taken together, its impact on normalizing cytokine and exerkine levels and the ROS and inflammatory response may represent a prophylactic and therapeutic approach to preventing NASH and hepatocellular carcinoma development, particularly by inhibiting SNARK oncogene among a high-risk population. This evidence concerns the gene NUAK2 and metabolic dysfunction-associated steatohepatitis.